Desvenlafaxine Succinate

DRUG5 trials

Sponsors

Hamilton Health Sciences Corporation, University of Ottawa, Pfizer, Hotel-Dieu Grace Healthcare

Conditions

HealthyMajor Depressive DisorderMenopausal Staging and Vasomotor Symptoms (for Females)Vascular DepressionVasomotor Symptoms

Phase 1

Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Volunteers

University of OttawaHealthy

Start: 2010-04-30End: 2011-12-31Target: 20Updated: 2011-08-08

Phase 3

Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women

Hamilton Health Sciences CorporationMajor Depressive Disorder, Menopausal Staging and Vasomotor Symptoms (for Females)

Start: 2009-06-30End: 2012-10-31Target: 90Updated: 2012-02-08

Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder

CompletedNCT01309542

PfizerMajor Depressive Disorder

Start: 2003-08-31End: 2006-03-31Updated: 2011-04-26

Phase 4

Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression

Hotel-Dieu Grace HealthcareVascular Depression

Start: 2013-12-31Target: 30Updated: 2015-03-19

Unknown Phase

Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients

TerminatedNCT01353963

PfizerMajor Depressive Disorder, Vasomotor Symptoms

Start: 2012-03-31End: 2012-08-31Updated: 2016-01-18

Related Papers

A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder.

2011-01-018 citations